OTCMKTS:MEOBF - Mesoblast Stock Price, Price Target & More

$1.22 -0.12 (-8.96 %)
(As of 04/20/2018 02:20 PM ET)
Previous Close$1.34
Today's Range$1.22 - $1.22
52-Week Range$0.95 - $2.42
Volume15,000 shs
Average Volume2,688 shs
Market Capitalization$634.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive MEOBF News and Ratings via Email

Sign-up to receive the latest news and ratings for MEOBF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolOTCMKTS:MEOBF
CUSIPN/A
WebN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares470,600,000

How to Become a New Pot Stock Millionaire

Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

Who are some of Mesoblast's key competitors?

Has Mesoblast been receiving favorable news coverage?

Media stories about MEOBF stock have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mesoblast earned a daily sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 45.41 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Mesoblast?

Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $1.22.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $634.14 million.


MarketBeat Community Rating for Mesoblast (MEOBF)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  55
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MEOBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEOBF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mesoblast (OTCMKTS:MEOBF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/20/2016 forward)

Earnings

Dividends

Mesoblast (OTCMKTS:MEOBF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mesoblast (OTCMKTS MEOBF) Insider Trading and Institutional Ownership History

Insider Trading History for Mesoblast (OTCMKTS:MEOBF)

Mesoblast (OTCMKTS MEOBF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Mesoblast (OTCMKTS MEOBF) News Headlines

Source:
DateHeadline
Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart FailureMesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure
finance.yahoo.com - April 18 at 10:01 AM
Mesoblast (MEOBF) Phase 3 Cell Therapy Trial For aGVHD Successfully Achieves Primary Endpoint - SlideshowMesoblast (MEOBF) Phase 3 Cell Therapy Trial For aGVHD Successfully Achieves Primary Endpoint - Slideshow
seekingalpha.com - February 24 at 9:46 AM
Star Entertainment Group And Other Top Growth StocksStar Entertainment Group And Other Top Growth Stocks
finance.yahoo.com - February 18 at 9:27 AM
FDA to fast track Mesoblasts cell therapy for heart failureFDA to fast track Mesoblast's cell therapy for heart failure
finance.yahoo.com - December 21 at 9:14 AM
Mesoblast’s Phase 3 Trial in Children With Acute Graft Versus Host Disease Completes EnrollmentMesoblast’s Phase 3 Trial in Children With Acute Graft Versus Host Disease Completes Enrollment
finance.yahoo.com - December 20 at 9:14 AM
What You Must Know About Mesoblast Limited’s (ASX:MSB) Financial HealthWhat You Must Know About Mesoblast Limited’s (ASX:MSB) Financial Health
finance.yahoo.com - December 14 at 9:20 AM
Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017
finance.yahoo.com - November 15 at 6:18 AM
Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis PatientsMesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis Patients
finance.yahoo.com - November 12 at 6:20 AM
Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart FailureMesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure
finance.yahoo.com - August 24 at 9:07 AM
Mesoblasts (MEOBF) CEO Silviu Itescu on Q3 2017 Results - Earnings Call TranscriptMesoblast's (MEOBF) CEO Silviu Itescu on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - May 26 at 3:56 AM
Mallinckrodt enters $21 million equity purchase agreement with MesoblastMallinckrodt enters $21 million equity purchase agreement with Mesoblast
www.bizjournals.com - February 17 at 7:34 PM
Mesoblasts (MEOBF) CEO Silviu Itescu on Q1 2017 Results - Earnings Call TranscriptMesoblast's (MEOBF) CEO Silviu Itescu on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 6:44 PM
Mesoblast widens losses on heart treatmentMesoblast widens losses on heart treatment
au.finance.yahoo.com - November 14 at 6:26 PM

SEC Filings

Mesoblast (OTCMKTS:MEOBF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Mesoblast (OTCMKTS MEOBF) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.